Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. Featured videos include: Pt.1: CANVAS Program …
Read More »Current Video Interview: Dr. Matthew Weir
Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have a special interview with one of the presenters at the AACE 26th Annual Scientific & Clinical Congress in Austin, Texas. Dr. Weir discusses the pros and cons of SGLT-2 inhibitors in clinical practice.
Read More »Dr. Matthew Weir Full Video
Dr. Matthew Weir discusses the pros and cons of SGLT-2 drugs with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine at the University of Maryland. Dr. …
Read More »Dr. Matthew Weir Part 1, SGLT2 Drugs and Kidney Disease
Dr. Matthew Weir talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the impact of SGLT2 drugs on the possible improvement of kidney disease. Dr. Matthew Weir, MD is a professor of medicine and director of Nephrology in the Department of Medicine …
Read More »Dr. Matthew Weir Part 2, Cardiovascular and Kidney Disease Prevention
At the the AACE 2017 convention in Austin, Texas, Dr. Matthew Weir and Diabetes in Control Publisher Steve Freed discuss the impact of SGLT2 drugs in helpful as well as possibly harmful ways. They also look at the need for safety studies for kidney disease. Dr. Matthew Weir, MD is …
Read More »Lance Sloan Full Interview
Dr. Lance Sloan talks with Diabetes in Control Publisher Steve Freed at AACE 2016. In this Exclusive Interview, Dr. Sloan discusses SGLT-associated DKA.
Read More »Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors (CVD-REAL)
Results from the ongoing first large real-world evidence study of its kind published in the American Heart Association.
Read More »Liraglutide and Acute Pancreatitis in Patients With Type 2 Diabetes
Study focuses on elevation of amylase and lipase levels as predictors of pancreatitis.
Read More »Did You Know: Safety Concerns for Diabetes Medications
When it comes to antidiabetic therapies, professionals should be aware of safety concerns with concentrated insulin formulations, metformin and renal function, and SGLT-2 inhibitors and DKA. See the breakdown of these safety issues by Tom Palma, RPh, MS, BCPS, and Greg Wiggers, PharmD, PhD, plus exclusive commentary by DIC Advisory Board member Dr. George Bakris.
Read More »SLGT-2 Inhibitors Gaining Traction as a Class in Preventing Cardiovascular Consequences
Are we experiencing the next “magic bullet” in type 2 diabetes?
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.